Well-established genetically engineered mouse models that utilize conditional alleles of oncogenic Kras, either alone or in combination with Trp53 mutation, recapitulate the stepwise progression of lung adenocarcinoma and phenocopy human therapeutic responses to standard-of-care treatment regimens [7]. This evidence concerns the gene KRAS and lung adenocarcinoma.